Kisqali
(Dalpiciclib)Phase 3Small molecule
Dalpiciclib is used to treat certain types of breast cancer, specifically hormone receptor-positive breast cancer in women. It works by slowing down the growth of cancer cells.[1] Kisqali is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Kisqali is one of 200 small molecule programs targeting Meningioma. It is currently in Phase 3.
6
Indications
33
Total Trials
26
Active Trials
199
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Kisqali
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Blenoxane
Bristol-Myers SquibbPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Tianeptine
PfizerPreclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer24 trials
Show 21 more trials
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06341894·1,163 enrolled
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05463601·132 enrolled
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Unknown status·—·Phase 1·NCT05586841·30 enrolled
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
Not yet recruiting·—·Phase 2·NCT06556862·155 enrolled
Dalpiciclib2 trials
Ovarian Cancer1 trial
Metastatic Colorectal Cancer1 trial
4 more indications
Esophageal Squamous Cell Carcinoma1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dalpiciclib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details